John Rondoni Sells 109 Shares of Inspire Medical Systems (NYSE:INSP) Stock

Inspire Medical Systems, Inc. (NYSE:INSP) insider John Rondoni sold 109 shares of Inspire Medical Systems stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $100.00, for a total transaction of $10,900.00. Following the completion of the sale, the insider directly owned 13,797 shares in the company, valued at approximately $1,379,700. The trade was a 0.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Inspire Medical Systems Stock Down 4.7%

NYSE INSP opened at $92.41 on Wednesday. The stock has a market capitalization of $2.69 billion, a P/E ratio of 62.86, a P/E/G ratio of 9.82 and a beta of 0.72. Inspire Medical Systems, Inc. has a 52-week low of $70.77 and a 52-week high of $203.12. The firm has a 50-day moving average price of $105.36 and a 200 day moving average price of $98.86.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.53. The company had revenue of $224.50 million for the quarter, compared to analysts’ expectations of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 EPS. On average, equities research analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Piper Sandler boosted their target price on shares of Inspire Medical Systems from $135.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Stifel Nicolaus set a $110.00 target price on shares of Inspire Medical Systems and gave the stock a “buy” rating in a research report on Monday, November 24th. Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, October 27th. Wolfe Research raised Inspire Medical Systems from a “peer perform” rating to an “outperform” rating and set a $180.00 price target on the stock in a research note on Tuesday, November 25th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Inspire Medical Systems in a research note on Monday, December 29th. Eleven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.35.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Manning & Napier Advisors LLC acquired a new stake in Inspire Medical Systems during the 3rd quarter valued at $32,000. Larson Financial Group LLC raised its holdings in shares of Inspire Medical Systems by 21,266.7% in the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after acquiring an additional 638 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Inspire Medical Systems in the third quarter valued at $49,000. Daiwa Securities Group Inc. lifted its position in shares of Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 130 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Inspire Medical Systems during the third quarter valued at $72,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Key Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire issued preliminary Q4 and FY‑2025 revenue results and initial 2026 revenue guidance that beat or met Street expectations (Q4 revenue guidance ~$268.9M–$269.1M vs. consensus ~$262.5M; FY‑2025 revenue ~$911.8M–$912.0M vs. consensus ~$905.3M; 2026 initial guidance ~ $1.0B). This reduces near‑term execution risk and supports growth visibility. Inspire announces preliminary revenue results and guidance
• Positive Sentiment: The company appointed Matt Osberg as EVP & Chief Financial Officer (joining in Q1 2026). A seasoned CFO can improve investor confidence in financial planning and reporting as Inspire scales revenue. Inspire appoints Matt Osberg as CFO
• Positive Sentiment: Coverage from JPM/market writeups highlights management’s positive messaging for 2026 and continued growth potential, reinforcing the guidance narrative presented at the J.P. Morgan Healthcare Conference. JPM26: Inspire projects a strong 2026
• Neutral Sentiment: Management presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript/slides available). Conference exposure can attract investor interest but doesn’t guarantee immediate buying. Conference transcript
• Neutral Sentiment: An unrelated med‑device peer (Impulse Dynamics) announced a CFO hire — industry hiring activity is background noise for Inspire but highlights competition for experienced finance talent. Impulse Dynamics CFO announcement
• Negative Sentiment: An insider (John Rondoni) sold 109 shares (about $10.9k) on Jan 9; the sale is small (0.78% ownership reduction) but can be read by some traders as modest insider profit‑taking. Insider John Rondoni sells 109 shares

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.